NantOmics Valuation, Funding & Investors

NantOmics is valued at $1.7B as of June 2015.

Last NantOmics valuation

$1.7B

Series A · Jun 2015

Last NantOmics funding round

$251M

Series A · Jun 2015

Cumulative funding NantOmics raised

$251M

across 1 funding round

Key investors in NantOmics

NantOmics Overview

About NantOmics

NantOmics is a Culver City-headquartered molecular diagnostics company that develops cloud-based molecular profiling tools, including the GPS Cancer test and OncoPlexDx Targeted Proteomic panel, to guide personalized cancer treatments for patients and oncologists. As a subsidiary of NantWorks, it delivers point-of-care insights into cancer biology through quantitative protein biomarkers and genomic profiles. NantOmics supports treatment strategies in clinical settings across the United States, with headquarters in California and integration into broader precision medicine platforms.


Founded

2012

HQ

United StatesLos Angeles, CA

Status

Privately held

Customer focus

B2B

Revenue model

Services, Product sales

Valuation

$1.7B (Jun 2015)

NantOmics Valuation

NantOmics is currently valued at $1.7B, based on its Series A in June 2015.

The $251M round was led by NantHealth.

NantOmics valuation by funding round

NantOmics valuation by funding round
DateStageValuation
Jun 2015Series A$1.7B

NantOmics Funding History

NantOmics has raised a total of $251M across 1 funding round.

NantOmics funding rounds

NantOmics funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jun 2015Series ANantHealth (lead)$251M$1.7BNantOmics, a molecular diagnostics arm of NantWorks founded by Patrick Soon-Shiong, specializes in precision medicine with a cloud-based infrastructure for processing thousands of genomes daily, computing genomic variances in near real-time, and correlating proteomic pathway analysis from tumor samples. It operates the nation’s only CAP- and CLIA-certified whole genome and quantitative proteomics laboratory, providing genomic insights like the GPS Cancer platform licensed to sister company NantHealth. In September 2015, it completed the acquisition of OncoPlex Diagnostics, a proteomics lab funded by Soon-Shiong subsidiaries since 2008. In June 2015, NantHealth invested a substantial portion of its capital in NantOmics, acquiring approximately 14.2% to 14.3% of the issued and outstanding membership interests for $52.5 million, as detailed in SEC filings and NantHealth's S-1 for its IPO. This investment gave NantHealth access to NantOmics' advanced lab capabilities to enhance its CLINICS platform, which integrates NantOS apps, GPS Cancer, and other tools. NantWorks operates as an ecosystem of interrelated entities, with Soon-Shiong orchestrating funding and M&A among subsidiaries like NantHealth, NantCell, and NantOmics. NantHealth's 2015 net revenue was $58.3 million with a $72 million net loss. Later, in 2016, NantHealth recorded a $29.8 million impairment on its NantOmics investment due to delayed GPS test sales growth and a $41 million loss from the equity method investment. The investment supported NantOmics' role in NantHealth's precision care platforms serving over 2,000 hospitals, 70 health plans, and 100 million patients.

Who has invested in NantOmics?

1 investor has backed NantOmics across its funding rounds, including NantHealth.

Lead investors include NantHealth.


NantOmics Investors

Investors in NantOmics by funding rounds participated
InvestorHQRoundsRoleFirst check

This data is available for Pro users. Sign up to see all 1 NantOmics investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by NantOmics

NantOmics has acquired 2 companies to date.

Last acquisition by NantOmics was on April 13th 2017. NantOmics acquired Genos for undisclosed valuation.


Latest Acquisitions by NantOmics

Genos
OncoPlexDx
Description
Genos is a consumer genomics company based in Mountain View, California, empowering individuals with personal control over their DNA data. The firm offers whole-genome sequencing kits that allow users to store and share genomic information selectively with researchers and partners. Genos facilitates community-driven research projects in rare diseases and traits through its data marketplace, connecting sequenced genomes to academic studies worldwide.
OncoPlexDx is a CLIA-certified laboratory in Rockville, Maryland, providing multiplex proteomics assays for cancer therapy selection. Analyzing 143 proteins via immunoassay, it guides precision treatment in breast, lung, and colorectal cancers, correlating with outcomes in 1,000 patient cohorts to avoid ineffective therapies.
HQ CountryUnited StatesUnited States
HQ City
San Francisco, CA
Washington, DC
Deal Date13 Apr 201710 Sep 2015
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all NantOmics acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by NantOmics

NantOmics has invested in 1 company to date.

Latest investment by NantOmics was on September 1st 2015. NantOmics invested in Translational Research Management in their $800K Seed round.


Latest Investments by NantOmics

Translational Research Management
Description
Translational Research Management is a Plymouth Meeting-headquartered organization building a network of over 100 community oncology practices across the United States. TRM facilitates access to more than 500 active clinical trials for cancer patients, partnering with pharma sponsors like Merck and Bristol Myers Squibb. The firm manages regulatory compliance and site activation nationwide.
HQ CountryUnited States
HQ City
Los Angeles, CA
Deal Date1 Sep 2015
RoundSeed
Raised$800K
Investors-
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all NantOmics investments and their VC round multiples.

Start Free Trial

NantOmics Competitors

NantOmics competitors include listed companies like Revvity, Dian Diagnostics Group and Vimian Group, and private ones like Iterative Health, Unite Us and NantHealth.

Public and private companies comparable to NantOmics
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Iterative HealthUnited StatesBoston, MAPrivate--$1.3B-
RevvityUnited StatesUnited StatesPublicly listed$2.9B$735M$16B6.6x
Dian Diagnostics GroupChinaChinaPublicly listed$1.5B$127M$1.7B1.4x
Vimian GroupSwedenSwedenPublicly listed$489M$119M$1.9B4.0x
Unite UsUnited StatesNew York City, NYPrivate--$1.6B-
NantHealthUnited StatesLos Angeles, CAPrivate$58M-$2B-

NantOmics Public Comps

NantOmics is still privately-owned, but its public comps include Dian Diagnostics Group, Vimian Group, JMDC, Indegene, Diagnostyka, Nutex Health, Ramsay Santé, Butterfly Network, Certara and Sinocare.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Dian Diagnostics Group$1.5B$127M1.4x1.4x16.4x12.2x
Vimian Group$489M$119M4.4x4.0x17.9x14.4x
JMDC$324M$88M5.0x4.6x18.4x17.9x
Indegene$366M$68M3.7x3.3x19.9x18.2x
Diagnostyka$637M$154M2.8x2.5x11.6x10.5x
Nutex Health$875M$288M2.0x2.0x6.0x6.4x
Ramsay Santé$6.2B$720M0.9x-8.0x-
Butterfly Network$98M($73M)20.6x17.6x(27.5x)(93.5x)

This data is available for Pro users. Sign up to see all NantOmics competitors and their valuation data.

Start Free Trial

Common questions about NantOmics

When was NantOmics founded?NantOmics was founded in 2012.
Where is NantOmics headquartered?NantOmics is headquartered in Los Angeles, CA, United States.
Is NantOmics publicly listed?No, NantOmics is a private, VC-backed company.
What is NantOmics' valuation?NantOmics was last valued at $1.7B in its Series A in June 2015.
How much funding has NantOmics raised?NantOmics has raised $251M across 1 funding round.
What was NantOmics' last funding round?NantOmics' last funding round was a $251M Series A in June 2015, led by NantHealth.
Who are NantOmics' investors?NantOmics' investors include NantHealth.
Which companies are comparable to NantOmics?Companies comparable to NantOmics include Iterative Health, Revvity, Dian Diagnostics Group, Vimian Group, Unite Us and NantHealth.
How many companies has NantOmics acquired?NantOmics has acquired 2 companies, including Genos and OncoPlexDx.
How many companies has NantOmics invested in?NantOmics has invested in 1 company, including Translational Research Management.
What was NantOmics' last investment?In September 2015, NantOmics invested in Translational Research Management's $800K seed round.

See companies similar to NantOmics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial